AORT Q4 2025 Earnings Call Summary | Stock Taper
Logo
Pricing Log In
AORT

AORT — Artivion, Inc.

NYSE

Q4 2025 Earnings Call Summary

February 12, 2026

Summary of AORT Q4 2025 Earnings Call

1. Key Financial Results and Metrics

  • Q4 2025 Results:
    • Adjusted revenues: $118.3 million, up 18.5% year-over-year.
    • Adjusted EBITDA: $22.7 million, a 29% increase from $17.6 million in Q4 2024.
    • Adjusted EBITDA margin: 19.2%, a 110 basis point improvement year-over-year.
  • Full Year 2025 Results:
    • Total adjusted revenues: $443.6 million, up 13% compared to 2024.
    • Adjusted EBITDA: $89.7 million, a 26% increase, with a margin of 20.2% (190 basis point improvement).
  • Cash Position: $64.9 million in cash, $215.1 million in debt, net leverage ratio improved to 1.8 from 3.8.

2. Strategic Updates and Business Highlights

  • Product Performance:
    • Stent grafts grew 36% in Q4, driven by AMDS in the U.S. and international markets.
    • On-X revenues increased 24% year-over-year, benefiting from market share gains and new clinical data.
    • Tissue processing revenue grew 6%, recovering from prior cybersecurity impacts.
  • Clinical Advancements:
    • Positive results from AMDS PERSEVERE and NEXUS TRIUMPH trials presented at the STS annual meeting.
    • AMDS PMA submission is on track for mid-2026 approval.
    • Progress on ARTISAN trial for Arecibo LSA, with FDA approval anticipated in 2029.

3. Forward Guidance and Outlook

  • 2026 Revenue Guidance: Expected constant currency growth of 10% to 14%, translating to reported revenues of $486 million to $504 million.
  • Segment Expectations:
    • Stent grafts: low twenties growth.
    • On-X: mid-teens growth.
    • Tissue: expected to remain flat.
    • BioGlue: mid-single digit growth.
  • Adjusted EBITDA for 2026: Projected between $105 million and $110 million, representing 18% to 22% growth over 2025.

4. Bad News, Challenges, or Points of Concern

  • Impact of Italian Payback Legislation: A $2.3 million revenue adjustment for estimated payback obligations was recorded, although future impacts are expected to be minimal.
  • Tissue Processing Decline: Full-year tissue processing revenue declined 3% compared to 2024, below expectations, primarily due to lingering effects from the cybersecurity incident.
  • R&D Spending Increase: Anticipated increase in R&D expenses as a percentage of sales from 7% to 8% in 2026, potentially impacting EBITDA growth rates.

5. Notable Q&A Insights

  • AMDS Growth: Management indicated that AMDS is still in its early stages, with significant growth potential as more accounts are opened and implants increase.
  • NEXUS Market Opportunity: The NEXUS device is expected to penetrate a nascent market with significant potential, but will require extensive training for surgeons.
  • Pricing Strategy: Management affirmed that the pricing for AMDS and NEXUS remains competitive, with favorable reimbursement conditions.
  • Future Marketing Initiatives: Plans to enhance marketing efforts for On-X, particularly targeting cardiologists, are in place but will take time to yield results.
  • Cybersecurity Incident Recovery: The impact of the previous year's cybersecurity incident is still being felt, particularly in the tissue processing segment, but overall business recovery is on track.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Artivion, Inc.'s performance and outlook.

← Q3 2025